M2Bio Sciences, Inc. is a nutraceutical biotechnology company that researches, develops and commercialises a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer's and Parkinson's. Our vision is to improve people’s quality of life by unleashing the full potential of medicinal cannabis and mushrooms. Our mission is to advance botanical-based medicine to the forefront. From seed to shelf and spore to store, we are driven by a passion for medicine and science. We live by the values of: Quality. Excellence. Science. Traceability. Accountability. Humility. M2Bio is listed and traded on the Over The Counter Bulletin Board of NASDAQ under the trading symbol “$WUHN”. The global market for legal cannabis is according to Euromonitor International anticipated to grow 1,283 percent in value of sales, in the next seven years, from US$12B to US$166B at a CAGR of 45.5 percent (2018-2025), subject to increased legalisation.